![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.210.987 |
Chemical and physical data | |
Formula | C30H32ClN3O8S |
Molar mass | 630.11 g·mol−1 |
| |
![]() ![]() |
Nelivaptan ( INN) [1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. [2] The drug had entered clinical trials for treatment of anxiety and depression. [3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted. [4]
It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.210.987 |
Chemical and physical data | |
Formula | C30H32ClN3O8S |
Molar mass | 630.11 g·mol−1 |
| |
![]() ![]() |
Nelivaptan ( INN) [1] (developmental codename SSR-149,415) is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. [2] The drug had entered clinical trials for treatment of anxiety and depression. [3] In July 2008, Sanofi-Aventis announced that further development of this drug had been halted. [4]
It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).